99 related articles for article (PubMed ID: 7999846)
1. Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients.
Kim SS; Hirose S; Tamura H; Nagasawa R; Tokushima H; Mitarai T; Isoda K
Adv Perit Dial; 1994; 10():282-5. PubMed ID: 7999846
[TBL] [Abstract][Full Text] [Related]
2. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
Sjöberg B; Anderstam B; Suliman M; Alvestrand A
Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
[TBL] [Abstract][Full Text] [Related]
3. The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels.
Borazan A; Aydemir S; Sert M; Yilmaz A
Mediators Inflamm; 2004 Dec; 13(5-6):361-4. PubMed ID: 15770053
[TBL] [Abstract][Full Text] [Related]
4. Hyperhomocysteinemia and protein damage in chronic renal failure and kidney transplant pediatric patients--Italian initiative on uremic hyperhomocysteinemia (IIUH).
Perna AF; Ingrosso D; Molino D; Galletti P; Montini G; Zacchello G; Bellantuono R; Caringella A; Fede C; Chimenz R; De Santo NG
J Nephrol; 2003; 16(4):516-21. PubMed ID: 14696753
[TBL] [Abstract][Full Text] [Related]
5. Hyperhomocysteinemia in children on renal replacement therapy.
Feinstein S; Sela BA; Drukker A; Becker-Cohen R; Raveh D; Gavendo S; Frishberg Y
Pediatr Nephrol; 2002 Jul; 17(7):515-9. PubMed ID: 12172765
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients.
Nakhoul F; Abassi Z; Plawner M; Khankin E; Ramadan R; Lanir N; Brenner B; Green J
Isr Med Assoc J; 2004 Apr; 6(4):213-7. PubMed ID: 15115259
[TBL] [Abstract][Full Text] [Related]
7. [Characteristics of hyperhomocysteinemia in dialysis patients].
Lovcić V; Kes P; Reiner Z
Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
[TBL] [Abstract][Full Text] [Related]
8. Relationship between hyperhomocysteinemia and atherosclerosis in chronic hemodialysis patients.
Taruangsri P; Ong-Ajyooth L; Ong-Ajyooth S; Chaiyasoot W; Leowattana W; Sritippayawan S; Vareesangthip K; Chanchairujira T; Vasuvattakul S; Shayakul C; Vanichakarn S
J Med Assoc Thai; 2005 Oct; 88(10):1373-81. PubMed ID: 16519382
[TBL] [Abstract][Full Text] [Related]
9. Hyperhomocysteinemia and the presence of cardiovascular disease are associated with kynurenic acid levels and carotid atherosclerosis in patients undergoing continuous ambulatory peritoneal dialysis.
Pawlak K; Mysliwiec M; Pawlak D
Thromb Res; 2012 Jun; 129(6):704-9. PubMed ID: 21906785
[TBL] [Abstract][Full Text] [Related]
10. [Effects of folic acid supplementation on hyperhomocysteinemia in CAPD patients: effects on unsaturated fatty acids].
Hirose S; Kim S; Matsuda A; Itakura Y; Matsumura O; Tamura H; Nagasawa R; Mitarai T; Isoda K
Nihon Jinzo Gakkai Shi; 1998 Jan; 40(1):8-16. PubMed ID: 9513377
[TBL] [Abstract][Full Text] [Related]
11. Folic acid treatment of hyperhomocysteinemia in dialysis patients.
Janssen MJ; van Guldener C; de Jong GM; van den Berg M; Stehouwer CD; Donker AJ
Miner Electrolyte Metab; 1996; 22(1-3):110-4. PubMed ID: 8676799
[TBL] [Abstract][Full Text] [Related]
12. Relationships between homocysteine and related amino acids in chronic hemodialysis patients.
McDonald SP; Whiting MJ; Tallis GA; Barbara JA
Clin Nephrol; 2001 Jun; 55(6):465-70. PubMed ID: 11434358
[TBL] [Abstract][Full Text] [Related]
13. Dimethylthetin treatment causes diffuse alveolar lung damage: a pilot study in a sheep model of Continuous Ambulatory Peritoneal Dialysis (CAPD).
Slow S; Vasudevamurthy M; Fraser R; McEntyre C; Lever M; Chambers S; George P
Exp Toxicol Pathol; 2007 Apr; 58(5):285-90. PubMed ID: 17175148
[TBL] [Abstract][Full Text] [Related]
14. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.
Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C
J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk assessment and homocysteine and leptin levels in peritoneal dialysis and hemodialysis patients.
Bekpinar S; Unlüçerçi Y; Genç S; Türkmen A
Adv Perit Dial; 2005; 21():80-4. PubMed ID: 16686291
[TBL] [Abstract][Full Text] [Related]
16. [Alteration of homocysteine before and after hemodialysis in chronic hemodialysis patients].
Wang HT; Peng YM; Liu H
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):266-8. PubMed ID: 14653086
[TBL] [Abstract][Full Text] [Related]
17. Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis.
Chuang CK; Lin SP; Chen HH; Chen YC; Wang TJ; Shieh WH; Wu CJ
Clin Chim Acta; 2006 Feb; 364(1-2):209-16. PubMed ID: 16087168
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with increased plasma homocysteine in patients using an amino acid peritoneal dialysis fluid.
Yang SY; Huang JW; Shih KY; Hsu SP; Chu PL; Chu TS; Wu KD
Nephrol Dial Transplant; 2005 Jan; 20(1):161-6. PubMed ID: 15572386
[TBL] [Abstract][Full Text] [Related]
19. [Risk factors for atherosclerotic vascular disease in patients on maintenance hemodialysis--with especial respect to reverse cholesterol transport system and hyperhomocysteinemia].
Kimura H; Yoshida H
Rinsho Byori; 2002 Aug; 50(8):793-801. PubMed ID: 12373816
[TBL] [Abstract][Full Text] [Related]
20. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients.
Chauveau P; Chadefaux B; Coudé M; Aupetit J; Hannedouche T; Kamoun P; Jungers P
Kidney Int Suppl; 1993 Jun; 41():S72-7. PubMed ID: 8320950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
